Antibodies designed as effective cancer vaccines

References

• Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12:898 - 910
   PubMed Web of Science ®Google Scholar
• Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J Clin Immunol 2002; 22:124 - 130
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007; 26:3594 - 3602
   PubMed Web of Science ®Google Scholar
• Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine 2007; 25:3032 - 3037
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005; 92:1358 - 1365
   PubMed Web of Science ®Google Scholar
• Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001; 84:1443 - 1446
   PubMed Web of Science ®Google Scholar
• Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunol 1989; 67:525 - 530
   PubMed Web of Science ®Google Scholar
• Austin EB, Robins RA, Baldwin RW, Durrant LG. Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst 1991; 83:1245 - 1248
   PubMed Web of Science ®Google Scholar
• Robins RA, Denton GW, Hardcastle JD, Austin EB, Baldwin RW, Durrant LG. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 1991; 51:5425 - 5429
   PubMed Web of Science ®Google Scholar
• Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57:10 - 14
   PubMed Web of Science ®Google Scholar
• Durrant LG, Buckley TJ, Denton GW, Hardcastle JD, Sewell HF, Robins RA. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994; 54:4837 - 4840
   PubMed Web of Science ®Google Scholar
• Durrant LG, Buckley DJ, Robins RA, Spendlove I. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int J Cancer 2000; 85:87 - 92
   PubMed Web of Science ®Google Scholar
• Durrant LG, Maxwell-Armstrong C, Buckley D, Amin S, Robins RA, Carmichael J, Scholefield JH. A neoadjuvant clinical trial in colorectal cancer patients of the human antiidiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 2000; 6:422 - 430
   PubMed Web of Science ®Google Scholar
• Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol 2000; 30:2944 - 2953
   PubMed Web of Science ®Google Scholar
• Maxwell-Armstrong CA, Durrant LG, Robins RA, Galvin AM, Scholefield JH, et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999; 45:593 - 598
   PubMed Web of Science ®Google Scholar
• Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Immunotherapy for colorectal cancer. Am J Surg 1999; 177:344 - 348
   PubMed Web of Science ®Google Scholar
• Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG. Vaccine-induced apoptosis: a novel clinical trial end point?. Cancer Res 2000; 60:3132 - 3136
   PubMed Web of Science ®Google Scholar
• Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F. Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer 2001; 92:414 - 420
   PubMed Web of Science ®Google Scholar
• Parsons T, Spendlove I, Nirula R, Writer M, Carter G, Carr F, Durrant LG. A novel CEA vaccine stimulates T cell proliferation, gammaIFN secretion and CEA specific CTL responses. Vaccine 2004; 22:3487 - 3894
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, et al. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an antiidiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res 2006; 12:7389 - 7396
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 2008; 128:148 - 154
   PubMed Web of Science ®Google Scholar
• Durrant LG, Denton GW, Jacobs E, Mee M, Moss R, Austin EB, et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours. Int J Cancer 1992; 50:811 - 816
   PubMed Web of Science ®Google Scholar
• Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 1993; 259:224 - 247
   PubMed Web of Science ®Google Scholar
• Zanetti M, Rossi F, Lanza P, Filaci G, Lee RH, Billetta R. Theoretical and practical aspects of antigenized antibodies. Immunol Rev 1992; 130:125 - 150
   PubMed Web of Science ®Google Scholar
• Amzel LM, Poljak RJ. Three-dimensional structure of immunoglobulins. Ann Rev Biochem 1979; 48:961 - 997
   PubMed Web of Science ®Google Scholar
• Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994; 31:169 - 217
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196:901 - 917
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Bilofsky H. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J Biol Chem 1977; 252:6609 - 6616
   PubMed Web of Science ®Google Scholar
• Padlan EA. Structural implications of sequence variability in immunoglobulins. PNAS 1977; 74:2551 - 2555
   PubMed Web of Science ®Google Scholar
• Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. Faseb J 1995; 9:133 - 139
   PubMed Web of Science ®Google Scholar
• Studnicka GM, Soares S, Better M, Williams RE, Nadell R, Horwitz AH. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Prot Eng 1994; 7:805 - 814
   PubMedGoogle Scholar
• Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927 - 948
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342:877 - 883
   PubMed Web of Science ®Google Scholar
• Tramontano A, Chothia C, Lesk AM. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 1990; 215:175 - 182
   PubMed Web of Science ®Google Scholar
• Sollazzo M, Billetta R, Zanetti M. Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding. Prot Eng 1990; 4:215 - 220
   PubMedGoogle Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. PNAS 1979; 76:4350 - 4354
   PubMed Web of Science ®Google Scholar
• Billetta R, Hollingdale MR, Zanetti M. Immunogenicity of an engineered internal image antibody. PNAS 1991; 88:4713 - 4717
   PubMed Web of Science ®Google Scholar
• Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J Exp Med 1993; 178:1795 - 1799
   PubMed Web of Science ®Google Scholar
• Li S, Polonis V, Isobe H, Zaghouani H, Guinea R, Moran T, Bona C, Palese P. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol 1993; 67:6659 - 6666
   PubMed Web of Science ®Google Scholar
• Kuzu Y, Kuzu H, Zaghouani H, Bona C. Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide. Int Immunol 1993; 5:1301 - 1307
   PubMed Web of Science ®Google Scholar
• Zaghouani H, Kuzu Y, Kuzu H, Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin. Eur J Immunol 1993; 23:2746 - 2750
   PubMed Web of Science ®Google Scholar
• Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, et al. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods 2001; 248:183 - 194
   PubMed Web of Science ®Google Scholar
• Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195:1653 - 1659
   PubMed Web of Science ®Google Scholar
• Ravetch JV. A full complement of receptors in immune complex diseases. J Clinical Investigation 2002; 110:1759 - 1761
   PubMed Web of Science ®Google Scholar
• Melief CJ. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Imunol 2003; 33:2645 - 2654
   PubMed Web of Science ®Google Scholar
• Strawbridge AB, Blum JS. Autophagy in MHC class II antigen processing. Curr Opin Immunol 2007; 19:87 - 92
   PubMed Web of Science ®Google Scholar
• Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:371 - 380
   PubMed Web of Science ®Google Scholar
• Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914 - 2923
   PubMed Web of Science ®Google Scholar
• Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fcgamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996; 157:541 - 548
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. PNAS 2005; 102:2910 - 2915
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Phillips B, Bot S, Bona C, Zaghouani H. Immunologic control of tumors by in vivo Fcgamma receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation. J Immunol 2006; 176:1363 - 1374
   PubMed Web of Science ®Google Scholar
• Steitz J, Bruck J, Steinbrink K, Enk A, Knop J, Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000; 86:89 - 94
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823 - 832
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355 - 366
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001; 194:481 - 489
   PubMed Web of Science ®Google Scholar
• Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2:1122 - 1128
   PubMed Web of Science ®Google Scholar
• Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188:1075 - 1082
   PubMed Web of Science ®Google Scholar
• Klinman DM, Sechler JM, Conover J, Gu M, Rosenberg AS. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol 1998; 160:2388 - 2392
   PubMed Web of Science ®Google Scholar
• Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001; 167:5549 - 5557
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?. J Immunol 1996; 157:1823 - 1826
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Nicchitta CV. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 2006; 27:368 - 373
   PubMed Web of Science ®Google Scholar
• Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404:770 - 774
   PubMed Web of Science ®Google Scholar
• Cawthon AG, Alexander-Miller MA. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol 2002; 169:3492 - 3498
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 2007; 7:1647 - 1664
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Rabussay D, Ottensmeier C, Mathiesen I, Kjeken R. Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol Biol 2008; 423:497 - 507
   PubMedGoogle Scholar
• Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421:852 - 856
   PubMed Web of Science ®Google Scholar
• Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 2003; 171:6339 - 6343
   PubMed Web of Science ®Google Scholar
• Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047 - 6055
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122 - 3131
   PubMed Web of Science ®Google Scholar
• Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157:105 - 132
   PubMed Web of Science ®Google Scholar